Report cover image

Asthma Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Dec 01, 2024
Length 135 Pages
SKU # FOB19410726

Description

Asthma Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Asthma Treatment Market

The asthma treatment market size was valued at USD 18.08 billion in 2019, and the market is now projected to grow USD 32.81 billion in 2032 exhibiting a CAGR of 4.6% during the forecast period of 2020-2032.

The appearance of COVID-19 posed some prospects in the asthma treatment market because any respiratory diseases became much more dangerous when this virus attacks the lungs. Symptomatic management of asthma and attempts to reduce progression of the illness to make a person less vulnerable to the severe course of COVID-19. Furthermore, the sales of inhalers and other asthma medication skyrocketed during the pandemic as people continued to cut their costs and made new worries about their health their top priority. The need for pulmonary care and regularly use of prescribed medications had to have driven the advancements and expanded marketing of asthma remedies.

The increase in the rate of chronic respiratory diseases especially asthma is helping to push the growth of the market for asthma treatments as asthma is the most prevalent chronic disease globally known. As observed previously, severe asthma still interferes with the Quality-of-life measure, and therefore the need for better drugs. Per the AAAAI survey done in 2016 an approximate of 8.3% of children in United States have asthma. There are also insights that the options of purchasing affordable and effective treatments will also remain crucial to the market’s development over the forecast period in addition.

One of the major trends in the asthma treatment market is the focus of leading pharma players on research and innovation to bring the best treatment line for asthma. Considering that asthma has a very broad patient pool globally including patient of all ages, many firms are developing drugs in clinical stages. For example, in September 2019, there was positive Phase III outcome of QVM149, an inhaled combination that controls asthmatic symptoms and lung function. Such clinical developments are anticipated to amplify the market more during the forecast period.

Comprehensive Analysis of Asthma Treatment Market

The asthma treatment market growth is rising at an exponential rate due to its market segmentation. This market expansion rightly provides a thorough market breakdown near to the industry considering the leading supply and demand forces. These segmentations are methodically segregated by treatment analysis, by route of administration analysis and by distribution channel analysis. By treatment analysis include long-term control medications and quick-relief medications. By route of administration analysis include injectable, oral, and inhalation. By distribution channel analysis include hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.

The North America region lead the asthma treatment market share by benefitting a market size of USD 9.40 billion in 2019 due to underdiagnosis of asthmatic patients.

The top players in the markets have a central responsibility in the healthcare industry to be sure of industrial prospectus development and to establish the market norms. These players include, AstraZeneca, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Mylan N.V., Boehringer Ingelheim International GmbH, Regeneron, Sanofi, Genentech, Inc. (F. Hoffmann-La Roche Ltd), Novartis AG, Sumitomo Dainippon Pharma Co., Ltd. these market players provide a level-playing competitive landscape.

In April 2020, Cipla Inc. announced the successful completion of a phase III clinical study for its generic asthma drug, fluticasone propionate and salmeterol inhalation powder, a generic equivalent of Advair Diskus 100/50 mcg.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2016-2027

Base Year 2019

Forecast Period 2020-2027

Historical Period 2016-2018

Unit Value (USD billion)

SegmentationBy Treatment

Long-Term Control Medications

Quick-Relief Medications

By Route of Administration

Injectable

Oral

Inhaled

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies & Drug Stores

Online Pharmacies

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)

Latin America (Brazil, Mexico, and the Rest of Latin America)

The Middle East & Africa (South Africa, GCC, and the Rest of the Middle East & Africa)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

135 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Asthma - by Key Regions - 2019
4.2. Pipeline Analysis
4.3. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
4.4. Regulatory Scenario - by Key Regions
4.5. An Overview of Emerging Treatments for Asthma
4.6. An Overview of Guidelines for the Diagnosis and Management of Asthma (EPR-3)
4.7. Reimbursement Scenario - by Key Regions
5. Global Asthma Treatment Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Treatment
5.2.1. Long-Term Control Medications
5.2.2. Quick-Relief Medications
5.3. Market Analysis, Insights and Forecast – By Route of Administration
5.3.1. Injectable
5.3.2. Oral
5.3.3. Inhaled
5.4. Market Analysis, Insights and Forecast – By Distribution Channel
5.4.1. Hospital Pharmacies
5.4.2. Retail Pharmacies & Drug Stores
5.4.3. Online Pharmacies
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
6. North America Asthma Treatment Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis – By Treatment
6.2.1. Long-Term Control Medications
6.2.2. Quick-Relief Medications
6.3. Market Analysis – By Route of Administration
6.3.1. Injectable
6.3.2. Oral
6.3.3. Inhaled
6.4. Market Analysis – By Distribution Channel
6.4.1. Hospital Pharmacies
6.4.2. Retail Pharmacies & Drug Stores
6.4.3. Online Pharmacies
6.5. Market Analysis – By Country
6.5.1. U.S.
6.5.2. Canada
7. Europe Asthma Treatment Market Analysis, Insights and Forecast, 2016-2027
7.1. Key Findings / Summary
7.2. Market Analysis – By Treatment
7.2.1. Long-Term Control Medications
7.2.2. Quick-Relief Medications
7.3. Market Analysis – By Route of Administration
7.3.1. Injectable
7.3.2. Oral
7.3.3. Inhaled
7.4. Market Analysis – By Distribution Channel
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies & Drug Stores
7.4.3. Online Pharmacies
7.5. Market Analysis – By Country/ sub-region
7.5.1. U.K.
7.5.2. Germany
7.5.3. France
7.5.4. Spain
7.5.5. Italy
7.5.6. Scandinavia
7.5.7. Rest of Europe
8. Asia pacific Asthma Treatment Market Analysis, Insights and Forecast, 2016-2027
8.1. Key Findings / Summary
8.2. Market Analysis – By Treatment
8.2.1. Long-Term Control Medications
8.2.2. Quick-Relief Medications
8.3. Market Analysis – By Route of Administration
8.3.1. Injectable
8.3.2. Oral
8.3.3. Inhaled
8.4. Market Analysis – By Distribution Channel
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies & Drug Stores
8.4.3. Online Pharmacies
8.5. Market Analysis – By Country/ sub-region
8.5.1. Japan
8.5.2. China
8.5.3. India
8.5.4. Australia
8.5.5. Southeast Asia
8.5.6. Rest of Asia Pacific
9. Latin America Asthma Treatment Market Analysis, Insights and Forecast, 2016-2027
9.1. Key Findings / Summary
9.2. Market Analysis – By Treatment
9.2.1. Long-Term Control Medications
9.2.2. Quick-Relief Medications
9.3. Market Analysis – By Route of Administration
9.3.1. Injectable
9.3.2. Oral
9.3.3. Inhaled
9.4. Market Analysis – By Distribution Channel
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies & Drug Stores
9.4.3. Online Pharmacies
9.5. Market Analysis – By Country/ sub-region
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East & Africa Asthma Treatment Market Analysis, Insights and Forecast, 2016-2027
10.1. Key Findings / Summary
10.2. Market Analysis – By Treatment
10.2.1. Long-Term Control Medications
10.2.2. Quick-Relief Medications
10.3. Market Analysis – By Route of Administration
10.3.1. Injectable
10.3.2. Oral
10.3.3. Inhaled
10.4. Market Analysis – By Distribution Channel
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies & Drug Stores
10.4.3. Online Pharmacies
10.5. Market Analysis – By Country/ sub-region
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2019)
11.3. Competition Dashboard
11.4. Comparative Analysis – Major Players
11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
11.5.1. AstraZeneca
11.5.1.1. Overview,
11.5.1.2. Products & services,
11.5.1.3. SWOT analysis,
11.5.1.4. Recent developments,
11.5.1.5. strategies,
11.5.1.6. financials (based on availability)
11.5.2. GlaxoSmithKline plc
11.5.2.1. Overview,
11.5.2.2. Products & services,
11.5.2.3. SWOT analysis,
11.5.2.4. Recent developments,
11.5.2.5. strategies,
11.5.2.6. financials (based on availability)
11.5.3. Teva Pharmaceutical Industries Ltd.
11.5.3.1. Overview,
11.5.3.2. Products & services,
11.5.3.3. SWOT analysis,
11.5.3.4. Recent developments,
11.5.3.5. strategies,
11.5.3.6. financials (based on availability)
11.5.4. Merck & Co., Inc.
11.5.4.1. Overview,
11.5.4.2. Products & services,
11.5.4.3. SWOT analysis,
11.5.4.4. Recent developments,
11.5.4.5. strategies,
11.5.4.6. financials (based on availability)
11.5.5. Mylan N.V.
11.5.5.1. Overview,
11.5.5.2. Products & services,
11.5.5.3. SWOT analysis,
11.5.5.4. Recent developments,
11.5.5.5. strategies,
11.5.5.6. financials (based on availability)
11.5.6. Boehringer Ingelheim International GmbH
11.5.6.1. Overview,
11.5.6.2. Products & services,
11.5.6.3. SWOT analysis,
11.5.6.4. Recent developments,
11.5.6.5. strategies,
11.5.6.6. financials (based on availability)
11.5.7. Regeneron
11.5.7.1. Overview,
11.5.7.2. Products & services,
11.5.7.3. SWOT analysis,
11.5.7.4. Recent developments,
11.5.7.5. strategies,
11.5.7.6. financials (based on availability)
11.5.8. Sanofi
11.5.8.1. Overview,
11.5.8.2. Products & services,
11.5.8.3. SWOT analysis,
11.5.8.4. Recent developments,
11.5.8.5. strategies,
11.5.8.6. financials (based on availability)
11.5.9. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
11.5.9.1. Overview,
11.5.9.2. Products & services,
11.5.9.3. SWOT analysis,
11.5.9.4. Recent developments,
11.5.9.5. strategies,
11.5.9.6. financials (based on availability)
11.5.10. Novartis AG
11.5.10.1. Overview,
11.5.10.2. Products & services,
11.5.10.3. SWOT analysis,
11.5.10.4. Recent developments,
11.5.10.5. strategies,
11.5.10.6. financials (based on availability)
11.5.11. Sumitomo Dainippon Pharma Co., Ltd.
11.5.11.1. Overview,
11.5.11.2. Products & services,
11.5.11.3. SWOT analysis,
11.5.11.4. Recent developments,
11.5.11.5. strategies,
11.5.11.6. financials (based on availability)
11.5.12. Other Prominent Players
11.5.12.1. Overview,
11.5.12.2. Products & services,
11.5.12.3. SWOT analysis,
11.5.12.4. Recent developments,
11.5.12.5. strategies,
11.5.12.6. financials (based on availability)
12. Strategic Recommendations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us